Bacterin To Present at the 5th Annual Maxim Group Growth Conference on

Bacterin To Present at the 5th Annual Maxim Group Growth Conference

BELGRADE, Mont. Mar. 12, 2012 - Bacterin International Holdings,

Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical

applications, will present at the 5th Annual Maxim Group Growth Conference, held on Monday, March 26, 2012, at the Grand Hyatt

Bacterin's chairman and CEO, Guy Cook, is scheduled to present

at 8:30am in the Carnegie room, with one-on-one meetings held throughout the day.

This full-day event will feature approximately 90 different

companies having group presentations and 1x1 meeting slots available. These companies span a broad range of sectors, such as Healthcare,

Specialty Finance, Energy, Infrastructure, Aerospace, Media & Technology.

For more information about the conference, please contact your

Maxim Group sales representative.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops,

manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the

growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth.

These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion

of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and

other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses

bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings

designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures that may be deemed

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant

risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer

to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates,"

"intends," "plans," "believes," "estimates," "projects," "forecasts,"

"strategy," "will," "goal," "target," "prospects," "potential," "optimistic,"

"confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical

fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties,

and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability

to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a

timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's

ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property;

the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness

of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes

in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills

and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including

actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under

the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking

statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except

James Carbonara, Regional Vice President, 646-755-7412

Brett Maas, 646-536-7331